Developer docs
API playgroundTry for free, no card

Search company profiles

Kuria Therapeutics

Full company profile

uuid0008wys

Namestring
Kuria Therapeutics
Legal namestring
Kuria Therapeutics, Inc.
Websiteurl
kuriatx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Kuria Therapeutics, Inc. is a preclinical-stage pharmaceutical company founded in 2022 and headquartered in Little Rock, Arkansas, developing novel small-molecule NRF2 activators for ophthalmic and dermal diseases. The company's lead asset is KTX-1161, a topical ophthalmic solution formulation of SCO-116, a macrocyclic compound that selectively inhibits the NRF2-KEAP1 protein-protein interaction through non-covalent binding — a mechanism that differentiates SCO-116 from covalent-binding NRF2 activators and is expected to support a favorable safety profile. The core scientific thesis is that activation of the NRF2 pathway, the master regulator of the cellular antioxidant response, can address the underlying mitochondrial dysfunction and oxidative stress that drive corneal endothelial diseases (Fuchs' dystrophy, post-cataract surgery cell loss) and retinal diseases (dry AMD). SCO-116 was discovered by SCOHIA PHARMA, a Japanese biotech, and is exclusively licensed to Kuria worldwide for topical ophthalmic and dermal applications under a June 2022 agreement that includes up to $67M in potential milestones plus tiered royalties to SCOHIA. The company plans to pursue Phase 2 clinical proof-of-concept studies directly in Fuchs' dystrophy and cataract surgery patients, with a stated exit orientation toward out-licensing or acquisition rather than building commercial infrastructure.

Kuria's primary revenue model is licensing and milestone payments tied to future clinical and commercial success of SCO-116/KTX-1161, not direct product sales. The company is funded by an initial seed round (September 2022), a non-dilutive NIH/NEI SBIR Fast Track Phase I/II grant of up to $2.3M awarded September 2025, and matching funds from the Arkansas Economic Development Commission. Go-to-market motion is event-driven and community-led: leadership actively presents at ARVO Annual Meetings (2024, 2025), the J.P. Morgan Healthcare Conference, Ophthalmology Futures Forums, InvestMidwest Venture Forum, Venture Connect, Texas Life Science Forum, and Southwest Venture Forum to engage key opinion leaders, investors, and prospective partners. The customer base is not commercial in the conventional sense — Kuria's near-term "customers" are clinicians, investigators, and patient advocacy groups who generate demand and clinical evidence, while the economic acquirers will be larger pharmaceutical partners or acquirers post-clinical milestones. The IP foundation rests on US Patent 11,518,763 (composition of matter, issued January 2023), solely owned by SCOHIA PHARMA but exclusively licensed to Kuria for the licensed fields. The leadership team of five executives — CEO Keith Ward, PhD (ex-Reata EVP & CDO, ex-Bausch & Lomb Global VP Pharmaceutical R&D); COO Misty Stevens, PhD, MBA; CDO Dave Flory, MBA (ex-Reata, ex-Unicycive); CMO W. Brooks Gentry, MD (29-year UAMS professor); and CTO Ralph Henry, PhD — brings concentrated NRF2 and ophthalmology development experience to a 1-10 person organization.

Short descriptiontext

Kuria Therapeutics is a preclinical-stage pharmaceutical company developing novel small-molecule NRF2 activators (lead: KTX-1161, a topical eye drop) for corneal endothelial diseases including Fuchs' dystrophy and for retinal diseases like dry AMD. The company is privately held, based in Little Rock, Arkansas, and out-licensed from SCOHIA PHARMA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLittle Rock, United States
HQ citystring
Little Rock
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, NRF2 activators, corneal endothelial disease, topical ophthalmic drugs, preclinical biotech
Industry4 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Ophthalmic Goods Manufacturing339115
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Ophthalmic Goods3851
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Under the licensing agreement with SCOHIA PHARMA, Kuria received exclusive worldwide rights to develop, manufacture, and commercialize SCO-116 for ophthalmic and dermal diseases. SCOHIA PHARMA receives an upfront payment and is eligible for up to USD 67 million in potential regulatory, development, and commercial milestone payments, plus tiered royalties as a percentage of net sales. This represents the company's primary revenue model: out-licensing or being acquired by a larger pharma company upon clinical milestones.

kuriatx.com
2Non-Dilutive Grant Funding
TypeProfessional Services
Description

Kuria has secured non-dilutive funding through NIH SBIR grants (up to $2.3M Fast Track Phase I/II from NEI) and matching funds from the Arkansas Economic Development Commission. These grants fund preclinical and IND-enabling development activities without diluting equity.

kuriatx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kuria Therapeutics develops a pipeline of topical ophthalmic drug candidates based on novel small-molecule NRF2 activators (lead compound SCO-116, formulated as KTX-1161 eye drops). The company targets corneal endothelial diseases such as Fuchs' dystrophy and cataract surgery-induced cell loss, with extension into retinal diseases including dry age-related macular degeneration and dermal conditions such as radiation dermatitis. Products are intended to be developed through clinical proof-of-concept and then out-licensed to larger pharmaceutical partners for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Preclinical proof-of-concept demonstrated: SCO-116 improved mitochondrial function in human fibroblasts in vitro, protected human retinal pigment epithelial cells from A2E/blue light insult in vitro, and preserved visual function and retinal structure in sodium iodate-induced geographic atrophy in rats in vivo.
+3 more records
Product overview1 text field

Kuria Therapeutics is a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic and dermal diseases. The core product is KTX-1161, a topical ophthalmic formulation of the novel small-molecule Nrf2 activator SCO-116. The company's pipeline includes treatments for corneal endothelial diseases (Fuchs' dystrophy, cataract surgery protection) and retinal diseases (dry age-related macular degeneration). The company operates under exclusive worldwide licensing from SCOHIA PHARMA for topical ophthalmic and dermal applications of SCO-116.

Product and service1 record
1KTX-1161
CategoryOphthalmic Pharmaceuticals
Description

Topical ophthalmic solution formulation of the novel small-molecule NRF2 activator SCO-116, being developed as a first-in-class disease-modifying therapy for corneal endothelial diseases including Fuchs' endothelial corneal dystrophy and for prevention of corneal endothelial cell loss associated with cataract surgery. Designed for prescription use by ophthalmologists and their patients with no approved pharmacological alternative.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-06-27
Description

Kuria Therapeutics and SCOHIA PHARMA entered into a strategic licensing agreement under which Kuria received exclusive worldwide rights to develop, manufacture, and commercialize locally delivered formulations of SCO-116 (novel NRF2 activator) for ophthalmic and dermal diseases (designated KTX-1161 for the topical ophthalmic product). SCOHIA PHARMA receives an upfront payment plus up to $67M in potential regulatory, development, and commercial milestones, plus tiered royalties on net sales. SCOHIA retains worldwide rights for SCO-116 for systemic formulations and indications other than eye and skin diseases. A Joint Steering Committee with representatives from both companies provides oversight.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Develops targeted therapies for retinal diseases including geographic atrophy (the dry AMD indication Kuria also targets). A relevant competitor in the retinal portion of Kuria's pipeline.

TypeEmerging player
Description

Developed Izervay for geographic atrophy secondary to dry AMD, acquired by Astellas in 2023. Most relevant direct competitor in the dry AMD / geographic atrophy space.

TypeDirect peer
Description

Specialty ophthalmology biotech developing therapeutics for retinal diseases. Comparable small-cap, single-platform ophthalmology biotech profile.

TypeBroad incumbent
Description

Global ophthalmology pharma and device company with broad portfolio across corneal, cataract, and retinal diseases. Source of Kuria's CEO's prior R&D leadership and a likely future commercial partner or acquirer.

TypeDirect peer
Description

Late clinical-stage ophthalmology specialty pharma developing therapeutics for front- and back-of-eye indications. Comparable size, therapeutic focus, and clinical-stage profile to Kuria.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for retinal and ophthalmic inflammatory diseases with novel mechanisms. Comparable emerging biotech profile focused on ophthalmology indications.

TypeOthers
Description

Developed and won FDA approval for omaveloxolone (Skyclarys), the first approved NRF2 activator. Closely comparable scientifically (NRF2 mechanism) and the source of much of Kuria's leadership team.

TypeDirect peer
Description

Specialty ophthalmology company developing novel drug-delivery formulations for front- and back-of-eye diseases. Comparable in applying innovative delivery (hydrogel inserts / topical) to ophthalmic indications.

TypeDirect peer
Description

European ophthalmology specialty company developing small-molecule therapeutics, including novel mechanisms targeting oxidative stress. Comparable specialty-pharma model and therapeutic focus.

TypeDirect peer
Description

Clinical-stage specialty ophthalmology pharma developing novel small-molecule therapies for dry eye disease and retinal disorders. Direct comparable in size, stage, and therapeutic-area focus to Kuria.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kuria Therapeutics

Ophthalmic Pharmaceuticalskuriatx.com

Kuria Therapeutics is a preclinical-stage pharmaceutical company developing novel small-molecule NRF2 activators (lead: KTX-1161, a topical eye drop) for corneal endothelial diseases including Fuchs' dystrophy and for retinal diseases like dry AMD. The company is privately held, based in Little Rock, Arkansas, and out-licensed from SCOHIA PHARMA.

What Kuria Therapeutics does

Kuria Therapeutics, Inc. is a preclinical-stage pharmaceutical company founded in 2022 and headquartered in Little Rock, Arkansas, developing novel small-molecule NRF2 activators for ophthalmic and dermal diseases. The company's lead asset is KTX-1161, a topical ophthalmic solution formulation of SCO-116, a macrocyclic compound that selectively inhibits the NRF2-KEAP1 protein-protein interaction through non-covalent binding — a mechanism that differentiates SCO-116 from covalent-binding NRF2 activators and is expected to support a favorable safety profile. The core scientific thesis is that activation of the NRF2 pathway, the master regulator of the cellular antioxidant response, can address the underlying mitochondrial dysfunction and oxidative stress that drive corneal endothelial diseases (Fuchs' dystrophy, post-cataract surgery cell loss) and retinal diseases (dry AMD). SCO-116 was discovered by SCOHIA PHARMA, a Japanese biotech, and is exclusively licensed to Kuria worldwide for topical ophthalmic and dermal applications under a June 2022 agreement that includes up to $67M in potential milestones plus tiered royalties to SCOHIA. The company plans to pursue Phase 2 clinical proof-of-concept studies directly in Fuchs' dystrophy and cataract surgery patients, with a stated exit orientation toward out-licensing or acquisition rather than building commercial infrastructure.

Kuria's primary revenue model is licensing and milestone payments tied to future clinical and commercial success of SCO-116/KTX-1161, not direct product sales. The company is funded by an initial seed round (September 2022), a non-dilutive NIH/NEI SBIR Fast Track Phase I/II grant of up to $2.3M awarded September 2025, and matching funds from the Arkansas Economic Development Commission. Go-to-market motion is event-driven and community-led: leadership actively presents at ARVO Annual Meetings (2024, 2025), the J.P. Morgan Healthcare Conference, Ophthalmology Futures Forums, InvestMidwest Venture Forum, Venture Connect, Texas Life Science Forum, and Southwest Venture Forum to engage key opinion leaders, investors, and prospective partners. The customer base is not commercial in the conventional sense — Kuria's near-term "customers" are clinicians, investigators, and patient advocacy groups who generate demand and clinical evidence, while the economic acquirers will be larger pharmaceutical partners or acquirers post-clinical milestones. The IP foundation rests on US Patent 11,518,763 (composition of matter, issued January 2023), solely owned by SCOHIA PHARMA but exclusively licensed to Kuria for the licensed fields. The leadership team of five executives — CEO Keith Ward, PhD (ex-Reata EVP & CDO, ex-Bausch & Lomb Global VP Pharmaceutical R&D); COO Misty Stevens, PhD, MBA; CDO Dave Flory, MBA (ex-Reata, ex-Unicycive); CMO W. Brooks Gentry, MD (29-year UAMS professor); and CTO Ralph Henry, PhD — brings concentrated NRF2 and ophthalmology development experience to a 1-10 person organization.

Kuria Therapeutics firmographics

Firmographics
Name
Kuria Therapeutics
Legal name
Kuria Therapeutics, Inc.
Website
https://kuriatx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Kuria Therapeutics is a preclinical-stage pharmaceutical company developing novel small-molecule NRF2 activators (lead: KTX-1161, a topical eye drop) for corneal endothelial diseases including Fuchs' dystrophy and for retinal diseases like dry AMD. The company is privately held, based in Little Rock, Arkansas, and out-licensed from SCOHIA PHARMA.
Ownership category
akta.pro rank

Kuria Therapeutics industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Ophthalmic Goods Manufacturing (339115)
SIC
Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Ophthalmic pharmaceuticals
  • NRF2 activators
  • Corneal endothelial disease
  • Topical ophthalmic drugs
  • Preclinical biotech

Where Kuria Therapeutics is headquartered

Location

Headquarters

HQ city
Little Rock
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kuria Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Under the licensing agreement with SCOHIA PHARMA, Kuria received exclusive worldwide rights to develop, manufacture, and commercialize SCO-116 for ophthalmic and dermal diseases. SCOHIA PHARMA receives an upfront payment and is eligible for up to USD 67 million in potential regulatory, development, and commercial milestone payments, plus tiered royalties as a percentage of net sales. This represents the company's primary revenue model: out-licensing or being acquired by a larger pharma company upon clinical milestones.
  2. Non-Dilutive Grant Funding: Kuria has secured non-dilutive funding through NIH SBIR grants (up to $2.3M Fast Track Phase I/II from NEI) and matching funds from the Arkansas Economic Development Commission. These grants fund preclinical and IND-enabling development activities without diluting equity.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Kuria Therapeutics product offering

Product offering

Core offering

Kuria Therapeutics develops a pipeline of topical ophthalmic drug candidates based on novel small-molecule NRF2 activators (lead compound SCO-116, formulated as KTX-1161 eye drops). The company targets corneal endothelial diseases such as Fuchs' dystrophy and cataract surgery-induced cell loss, with extension into retinal diseases including dry age-related macular degeneration and dermal conditions such as radiation dermatitis. Products are intended to be developed through clinical proof-of-concept and then out-licensed to larger pharmaceutical partners for commercialization.

Product overview

Kuria Therapeutics is a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic and dermal diseases. The core product is KTX-1161, a topical ophthalmic formulation of the novel small-molecule Nrf2 activator SCO-116. The company's pipeline includes treatments for corneal endothelial diseases (Fuchs' dystrophy, cataract surgery protection) and retinal diseases (dry age-related macular degeneration). The company operates under exclusive worldwide licensing from SCOHIA PHARMA for topical ophthalmic and dermal applications of SCO-116.

Differentiator

Problem solved

Functional benefit

Products and services

  • KTX-1161 Topical ophthalmic solution formulation of the novel small-molecule NRF2 activator SCO-116, being developed as a first-in-class disease-modifying therapy for corneal endothelial diseases including Fuchs' endothelial corneal dystrophy and for prevention of corneal endothelial cell loss associated with cataract surgery. Designed for prescription use by ophthalmologists and their patients with no approved pharmacological alternative.

Quantifiable outcome

  • Preclinical proof-of-concept demonstrated: SCO-116 improved mitochondrial function in human fibroblasts in vitro, protected human retinal pigment epithelial cells from A2E/blue light insult in vitro, and preserved visual function and retinal structure in sodium iodate-induced geographic atrophy in rats in vivo.
  • +3 more outcomes

Companies that use Kuria Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Kuria Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kuria Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SCOHIA PHARMA, Inc.coreTechnology or Integration · 27 June 2022Kuria Therapeutics and SCOHIA PHARMA entered into a strategic licensing agreement under which Kuria received exclusive worldwide rights to develop, manufacture, and commercialize locally delivered formulations of SCO-116 (novel NRF2 activator) for ophthalmic and dermal diseases (designated KTX-1161 for the topical ophthalmic product). SCOHIA PHARMA receives an upfront payment plus up to $67M in potential regulatory, development, and commercial milestones, plus tiered royalties on net sales. SCOHIA retains worldwide rights for SCO-116 for systemic formulations and indications other than eye and skin diseases. A Joint Steering Committee with representatives from both companies provides oversight.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Kuria Therapeutics competitors and assessment

Company assessment

Emerging players

  • Apellis Pharmaceuticals: Develops targeted therapies for retinal diseases including geographic atrophy (the dry AMD indication Kuria also targets). A relevant competitor in the retinal portion of Kuria's pipeline.
  • Iveric Bio (Astellas): Developed Izervay for geographic atrophy secondary to dry AMD, acquired by Astellas in 2023. Most relevant direct competitor in the dry AMD / geographic atrophy space.
  • Annexon, Inc. Clinical-stage biotech developing therapeutics for retinal and ophthalmic inflammatory diseases with novel mechanisms. Comparable emerging biotech profile focused on ophthalmology indications.

Direct peers

  • Outlook Therapeutics: Specialty ophthalmology biotech developing therapeutics for retinal diseases. Comparable small-cap, single-platform ophthalmology biotech profile.
  • Ocuphire Pharma: Late clinical-stage ophthalmology specialty pharma developing therapeutics for front- and back-of-eye indications. Comparable size, therapeutic focus, and clinical-stage profile to Kuria.
  • Ocular Therapeutix: Specialty ophthalmology company developing novel drug-delivery formulations for front- and back-of-eye diseases. Comparable in applying innovative delivery (hydrogel inserts / topical) to ophthalmic indications.
  • Nicox SA: European ophthalmology specialty company developing small-molecule therapeutics, including novel mechanisms targeting oxidative stress. Comparable specialty-pharma model and therapeutic focus.
  • Aldeyra Therapeutics: Clinical-stage specialty ophthalmology pharma developing novel small-molecule therapies for dry eye disease and retinal disorders. Direct comparable in size, stage, and therapeutic-area focus to Kuria.

Broad incumbents

  • Bausch + Lomb: Global ophthalmology pharma and device company with broad portfolio across corneal, cataract, and retinal diseases. Source of Kuria's CEO's prior R&D leadership and a likely future commercial partner or acquirer.

Others

  • Reata Pharmaceuticals: Developed and won FDA approval for omaveloxolone (Skyclarys), the first approved NRF2 activator. Closely comparable scientifically (NRF2 mechanism) and the source of much of Kuria's leadership team.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Kuria Therapeutics social profiles

Digital presence

Kuria Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kuria Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Kuria Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kuria Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kuria Therapeutics

What does Kuria Therapeutics do?

Kuria Therapeutics develops a pipeline of topical ophthalmic drug candidates based on novel small-molecule NRF2 activators (lead compound SCO-116, formulated as KTX-1161 eye drops). The company targets corneal endothelial diseases such as Fuchs' dystrophy and cataract surgery-induced cell loss, with extension into retinal diseases including dry age-related macular degeneration and dermal conditions such as radiation dermatitis. Products are intended to be developed through clinical proof-of-concept and then out-licensed to larger pharmaceutical partners for commercialization.

Is Kuria Therapeutics a public or private company?

Kuria Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kuria Therapeutics founded?

Kuria Therapeutics was founded in 2022. It employs 1 to 10 people.

Where is Kuria Therapeutics based?

Kuria Therapeutics is headquartered in Little Rock, United States, in the North America region.

How does Kuria Therapeutics make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are non-Dilutive Grant Funding.

Who are Kuria Therapeutics's main competitors?

Emerging players on record are Apellis Pharmaceuticals, Iveric Bio (Astellas) and Annexon, Inc.. Direct peers are Outlook Therapeutics, Ocuphire Pharma, Ocular Therapeutix, Nicox SA and Aldeyra Therapeutics. Bausch + Lomb is listed as a broad incumbent. Reata Pharmaceuticals is listed as an others.

Does Kuria Therapeutics have an API?

No public API is recorded for Kuria Therapeutics.

What industry is Kuria Therapeutics in?

Kuria Therapeutics's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsKuria Therapeutics Closes Initial Funding RoundKuria Therapeutics has closed its initial funding round to support preclinical development and manufacturing activities for its lead ophthalmic product candidate. The undisclosed funds will be used to advance R&D ahead of a planned Series A raise, focusing on selecting a lead formulation and initiating IND-enabling work. Kuria is developing the topical ophthalmic formulation KTX-1161 under a license from Scohia Pharma.BioSpaceKuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 ActivatorKuria Therapeutics closed its first fundraising round to support preclinical development of its lead ophthalmic product candidate, KTX-1161, a topical Nrf2 activator. The funding will cover formulation selection, proof-of-concept studies, and IND-enabling manufacturing. The company plans two parallel Phase 2 studies for Fuchs' dystrophy and post-surgical corneal endothelial loss.ZapierKuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 ActivatorKuria Therapeutics has closed its initial fundraising round to support the preclinical development of KTX-1161, a novel topical ophthalmic formulation licensed from SCOHIA PHARMA. The funding will facilitate lead selection, proof-of-concept studies, and IND-enabling manufacturing activities for the company's Nrf2 activator asset. Kuria intends to evaluate the drug's efficacy in two parallel Phase 2 clinical trials targeting Fuchs’ dystrophy and corneal endothelial cell loss associated with surgery.